Rare case of classic Hodgkin lymphoma in a patient with ulcerative colitis Authors: Nicole Allyson Chua, Jose Sollano Jr Published: 2024 ABSTRACT SummaryPrimary gastrointestinal tract lymphoma (PGIL) is a rare form of presentation of gastrointestinal tract (GI) lymphomas. Inflammatory bowel disease (IBD) and the use of thiopurines are known risk factors for its appearance. We report a male patient in his early 70s treated only with mesalamine for ulcerative colitis (UC) for the past 6 years. He was admitted due to COVID-19 and anaemia secondary to massive haematochezia. The patient underwent total colectomy with end ileostomy, with intraoperative proctoscopy. Tissue biopsy demonstrated typical features of UC; however, atypical lymphoid proliferation of the regional lymph nodes with histological and immunochemical staining results was suggestive of classic Hodgkin lymphoma, nodular sclerosis subtype. The patient was treated with adriamycin, vinblastine and dacarbazine chemotherapy initially successful after 1 session but later opted for palliative care. Due to its rarity, lymphoid neoplasms occurring in the context of IBD are poorly known. Background Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel disease (IBD) of unknown aetiology. The epidemiology of IBD has changed, with the incidence rates of traditionally high-incidence areas such as Europe and the USA remaining relatively stable,1 while IBD has become more prevalent in previously low-incidence areas, such as Asia.2 IBD is becoming a major public health burden owing to increasing numbers of prevalent cases, deaths and disability-adjusted life years. In 2019, there were approximately 4.9 million cases of IBD worldwide, with China and the USA having the highest number of cases.3 Patients with IBD encounter a number of complications, and these may be related to the chronic inflammatory process 4 5 or due to the concomitant drug therapy. Primary gastrointestinal tract lymphoma (PGIL) describes the lymphoma that originates in the gastrointestinal tract, representing only 5%–10% of all lymphomas and up to 20% of extranodal lymphomas.6 Predisposing conditions for gastrointestinal lymphoma include Helicobacter pylori infection, IBD, autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus or coeliac disease and immunosuppressed states such as congenital and acquired immunodeficiency syndromes. The risk of colorectal cancer has been estimated to be 0.5%–1% per year after 8–10 years of disease in patients with extensive UC.7 8 Among the drugs that favour the development of lymphoma, thiopurines and anti-tumor necrosis factor (TNF) biological therapy were implicated.711 The most commonly affected site of the gastrointestinal tract is the stomach, followed by the small intestine and ileocecal region. Although the colorectal region can be compromised in up to 20% of PGIL,1214 primary colorectal lymphoma is very rare, only constituting approximately 3% of all PGIL and 0.3% of all gastrointestinal neoplasms.1416 Similarly, primary colorectal lymphoma is mainly a NHL, with diffuse large B-cell lymphoma (DLBCL) being the most frequent (25% of all NHL),14 15 as what occurs in other areas of the gastrointestinal tract. Due to its rarity, lymphoid neoplasms occurring in the context of IBD are poorly known.17 Case presentation We report a case of a man in his early 70s, diabetic (non-insulin requiring), previous 10 pack-year smoker, with a first-degree relative diagnosed with colorectal cancer. He was diagnosed with UC of 6 years of evolution, initially presenting with intermittent bloating, crampy left hemi-abdominal pain and occasional blood-tinged soft to water stools, in treatment with only 5-ASA (mesalamine), with last colonoscopy done in 2016, showing ulcerative proctocolitis with mild activity and the rest of the surrounding quiescent mucosa. He was lost to follow-up for 2 years, due to the COVID-19 pandemic, until he consulted for bloody diarrhoea occurring more than 10 times per day, easy fatigability, 10-pound weight loss in a span of 2 months and generalised body malaise with abdominal pain. The examination revealed generalised pallor, non-palpable cervical, axillary inguinal lymph nodes and unremarkable abdomen. Investigations CT of the abdomen and pelvis with intravenous contrast revealed a polypoid soft tissue rectal mass (2.6 × 2.0 × 3.1 cm) with luminal narrowing, approximately 3.5 cm from the anal verge (see figure 1a), and enlarged retroperitoneal, mesenteric and left external iliac lymph nodes; largest is approximately 4.95 × 3.1 cm in the para-aortic region (see figure 1b). Colonoscopy was performed which revealed findings suggestive of chronic UC with severe activity. Colonic mucosa from rectum onwards until the proximal transverse colon revealed oedema, erythema, friability, granularity, mucosal haemorrhages and ulcers (see figure 2a). Multiple pseudopolyps were seen in the level of the sigmoid and rectum (see figure 2b). There was no cobblestoning, fissures, strictures or masses. Multiple biopsies of the pseudopolyps taken from the rectum revealed histopathological findings of tubulovillous adenoma. Abdominal CT scan done one month apart (left to right): showing (a) a polypoid soft tissue rectal mass, unchanged; (b) decreased size of multiple enlarged abdominopelvic lymph nodes; and (c) interval appearance of fluid collection in the region of the levator ani with a peripheral enhancement pattern suggestive of an abscess. Colonoscopy findings are suggestive of chronic ulcerative colitis with severe activity: (a) colonic mucosa from rectum onwards until the proximal transverse colon revealed edema, erythema, friability, granularity, mucosal hemorrhages, and ulcers; (b) presence of multiple pseudopolyps at the rectosigmoid. The patient was treated as having acute severe UC and started initially on intravenous steroids and then prednisone 40 mg orally once per day and mesalamine 500 mg orally three times per day. Over a 4-week period, his symptoms regressed and steroids were slowly tapered. Repeat CT of the abdomen and pelvis with intravenous contrast revealed a stable polypoid soft tissue rectal mass in the rectum (see figure 1a), interval demonstration of circumferential rectal wall thickening with air locules (see figure 1c), interval appearance of fluid collection in the region of the levator ani with a peripheral enhancement pattern (see figure 1c) possibly infected/abscess formation (2.6 × 2.0 x 3.1 cm) and interval regression of lymphadenopathies (see figure 1b). However, he developed recurrence of symptoms, now with massive haematochezia and a palpable, solitary, tender, 2.5 × 2.5 cm perianal abscess (see figure 3a), after steroids were reduced to 10 mg/day, which led to his subsequent readmission after 1 month. Primary considerations for the case at this time were IBD-UC in flare, IBD-CD in flare, gastrointestinal tuberculosis and Clostridium difficile colitis. (a) a palpable, solitary, tender, perianal abscess; (b) the previously noted perianal abscess after surgical incision and drainage. Complete blood counts revealed haemoglobin of 94 g/L, white cell count of 10.16 × 109 /L and platelet count of 341 × 109 /L. Serum chemistry revealed hyponatraemia, hypoalbuminaemia, elevated inflammatory markers (CRP, D-dimer and ferritin) and elevated carcinoembryonic antigen (CEA) at 6.03. COVID-19 RT-PCR was positive for SARS-CoV2, for which the patient completed a 3-day course of intravenous remdesivir and tocilizumab 400 mg intravenously for two doses at 12-hour intervals. Stool analysis did not reveal any parasites and was negative for Clostridium difficile toxins A and B. Incision and drainage of the perianal abscess (see figure 3b) revealed culture results of Escherichia coli extended-spectrum beta-lactamases (ESBL)-positive and Klebsiella pneumoniae, for which culture-guided antibiotics were given. Due to persistent haematochezia in spite of intravenous steroids and multiple transfusions of packed red blood cells, the patient underwent total colectomy with end ileostomy, intraoperative proctoscopy (see figure 4). Grossly, the entire colonic mucosa appears pale, flattened and leather-like with loss of haustrations (see figure 4a); mucosal ulcers present in a scattered manner and more prominent in the distal portion and sigmoid colon, measuring 0.2 cm to 1.6 × 1.6 cm in diameter (see figure 4b); ileal mucosa is unremarkable (see figure 4c). Histological examination of the large intestine beginning in the rectosigmoid revealed mild-to-moderate chronicity changes in the form of crypt distortion and villiform change of the surface epithelium, with the degree of active inflammation varying from minimal to severe with ulcer formation (see figure 5a). In all sections taken, the inflammatory process and sequelae, like fibrosis, are absent in the submucosa, muscularis propria and pericolic fat, with evident regenerative changes such as nuclear enlargement and hyperchromasia. The rectum showed tubulovillous adenomas with foci of high-grade dysplasia (see figure 5b). There was atypical lymphoid proliferation involving predominantly the regional lymph nodes and portions of the pericolic fat and minimally the mucosa and submucosa of the large intestine (see figure 5c). Immunohistochemical staining was consistent with classic Hodgkin lymphoma (HL), nodular sclerosis and nuclear grade 2. The terminal ileum was unremarkable (see figure 5d). Intraoperative findings reveal (a) pale, flattened, leather-like colonic mucosa with loss of colonic haustrations; (b) presence of scattered mucosal ulcers in the distal portion and sigmoid colon; and (c) grossly normal-appearing ascending colon, cecum and terminal ileum. Histologic findings show (a) mild to moderate chronicity changes in the form of cryptdistortion and villiform change of the surface epithelium, with the degree of activeinflammation varying from minimal to severe with ulcer formation; (b) tubulovillous adenomas with foci ofhigh-grade dysplasia (rectum); (c) atypical lymphoid proliferation involving predominantly theregional lymph nodes and portions of the pericolic fat and minimally the mucosa andsubmucosa of the large intestine; and (d) unremarkable terminal ileum. Positron emission tomography (PET)/CT scan done 1 month later showed hypermetabolic lobulated mass in the grossly unchanged prominent rectal stump, suspicious for a neoplastic process (see figure 6a); hypermetabolic lobulated mass and consolidation with a suspicious area of hypoenhancement in the right upper lung lobe, neoplastic versus inflammatory (see figure 6b) and prominent to enlarged hypermetabolic cervical, mediastinal, retroperitoneal and bilateral external iliac chain lymph nodes, which likely represents a lymphoproliferative process (see figure 6c). Bone marrow aspiration biopsy revealed no evidence of lymphoma. PET/CT scan reveals (a) a hypermetabolic lobulated mass in the grossly unchanged prominent rectalstump, suspicious for a neoplastic process; (b) hypermetabolic lobulated mass and consolidation with a suspicious area of hypoenhancement in the right upper lung lobe, neoplastic versus inflammatory; and (c) prominent to enlarged hypermetabolic cervical, mediastinal, retroperitoneal andbilateral external iliac chain lymph nodes, likely represents lymphoproliferative process. Treatment, outcome and follow-up The patient was referred to medical oncology and was treated as a case of primary intestinal classic HL (advanced stage) with concomitant UC. Chemotherapy with adriamycin hydrochloride, vinblastine sulfate and dacarbazine was initiated. Pulmonary function test showed moderate-to-severe obstructive defect with a mild restrictive defect with mildly reduced DLCO. Due to this, bleomycin was omitted since the patient was noted to be at high risk for bleomycin-induced pneumonitis after risk stratification by the pulmonology service. However, 10 days after his first cycle of chemotherapy, he developed severe febrile neutropenia and pneumonia. After recovery, the patient opted for palliative care (figure 7) and eventually succumbed to death 5 months later. This figure shows the timeline of events when the patient was first diagnosed with UC until he developed primary internal classic HL. Discussion IBD may contribute to the development of lymphoproliferative disorders, as chronic inflammation itself plays a role in lymphomagenesis. The duration of the disease appears to be an independent risk factor for lymphoma. The risk of lymphoma in patients with IBD is mainly associated with the use of immunosuppressive drugs (such as thiopurines or anti-TNF)—but evidence is limited to case studies.1 6 10 18 Most of the thiopurine-promoted lymphomas are attributed to the cytotoxic effects of thiopurines on Epstein–Barr virus (EBV)-specific immune cells that prevent proliferation of EBV-infected B lymphocytes. Hospital-based studies have shown a definite increased risk of lymphoma, whereas population-based studies failed to show such increased risk.1921 In the meta-analysis by Kotlyar et al. in 2014, patients with IBD who are taking thiopurines have a nearly sixfold higher incidence of lymphoma when compared with the general population. The pooled standardised incidence ratios (SIR) for lymphoma was 4.92 (95% CI 3.10 to 7.78). Population studies demonstrated an increased risk among current thiopurine users (SIR=5.71; 95% CI 3.72 to 10.1) but not former users (SIR=1.42; 95% CI 0.86 to 2.34). Men have a greater risk than women (relative risk=1.98; p<0.05); both sexes were at increased risk for lymphoma (SIR for men=4.50; 95% CI 3.71 to 5.40 and SIR for women=2.29; 95% CI 1.69 to 3.05). Patients younger than 30 years had the highest relative risk (SIR=6.99; 95% CI 2.99 to 16.4); younger men had the highest risk. The absolute risk was highest in patients older than 50 years (1:354 cases per patient-year, with a relative risk of 4.78). In our case, our patient had UC of 6-year duration with multiple remissions of the disease and was only treated with mesalamine at subtherapeutic doses (1.5 g/day) and with some cycle of isolated steroids, not being associated with any of the expected drugs. Given the form of presentation, the differential diagnosis was a challenge due to the unusual way of debut, and finally after imaging tests and histopathological and immunohistochemical techniques, the diagnosis was reached and treatment was instituted. PGIL is infrequent, constituting only 1%–4% of all gastrointestinal neoplasms,12 15 22 and the most frequently developed lymphomas in IBD19 were NHL, which represented 494/589 [83.9%] of described lymphoid disorders, whereas Hodgkin’s lymphomas accounted for 16.5%. Among NHL, the most represented histological subtypes in patients with IBD were DLBCL and follicular lymphoma, which accounted for 30% [146/494] and 13% [65/494] of described cases, respectively. Current evidence on HL and IBD, limited to case reports, cohorts and systematic reviews,7 17 18 23 suggests an association between UC and Hodgkin disease is very rare. The diagnosis of HL can be a challenge. Classic HL is based on the identification of mononucleated Hodgkin cells and multinucleated giant cells termed Reed-Sternberg cells, within an inflammatory environment.18 Common presenting symptoms of gastrointestinal HL include abdominal pain, loss of appetite, weight loss, bleeding, vomiting, changes in bowel habits, fever and night sweats—all of which may be non-specific and may vary according to the involved site. The presence of underlying IBD may mask the diagnosis of HL such as in our case, because they may present the same way. Nodular sclerosis classical HL is the most frequent subtype of HL in North America and Europe and is mostly seen in young adults (peak incidence at 15–35 years of age). It is a less-frequent classic HL subtype in older adults, in immunosuppressed individuals and in developing countries. It presents most commonly with mediastinal disease. In our case, our patient was diagnosed histologically with this HL subtype, but he presented atypically (ie, older Asian adult, immunosuppressed, known UC presenting with gastrointestinal symptoms and no thiopurine use). Under the current first-line treatments of adriamycin, bleomycin, vinblastine and dacarbazine regimen, classic HL-nodular sclerosis grade 2 is an independent indicator for worse progression-free survival rates.24 This case report adds to the limited number of cases with the same disease condition, which can aid healthcare professionals to have better assessment and diagnostic approach and institute earlier treatment. Learning points There is a correlation between the use of immunomodulators and lymphoma development. There is a correlation between the use of immunomodulators and lymphoma development. Lymphoma can emerge in inflammatory bowel disease patients even without the use of thiopurine or anti-TNF therapy, and physicians must be aware of this possibility. Lymphoma can emerge in inflammatory bowel disease patients even without the use of thiopurine or anti-TNF therapy, and physicians must be aware of this possibility. Combined multidisciplinary approach is warranted to treat both the coexisting conditions. Combined multidisciplinary approach is warranted to treat both the coexisting conditions.